Invitation to Medivir's R&D Day on March 2, 2020
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET.
The presentations will, among other things, address new clinical results from the phase Ia study with MIV-818 in liver cancer patients. Members of Medivir's management team and Professor Jeff Evans, Director of the Institute of Cancer Sciences at the University of Glasgow, will give presentations.
The meeting will be held at Helio GT30, Grev Turegatan 30 in Stockholm, on March 2 at 14:00 to 16:30 CET.
The presentations will be held in English. The event will also be streamed via a link on the website: www.medivir.com. The presentations will be available on Medivir's website.
To register, please send an e-mail to: info@cordcom.se
| Agenda | ||
| 13.30-14.00 | Registration and coffee | |
| 14.00-14.10 | Introduction | Dr Uli Hacksell, CEO Medivir |
| 14.10-14.40 | Hepatocellular carcinoma (and ihCCA) - unmet needs | Prof Jeff Evans, University of Glasgow |
| 14.40-15.00 | The liver cancer market | Dr Christina Herder, COO and EVP, Medivir |
| 15.00-15.15 | Break | |
| 15.15-15.30 | The nucleotide prodrug platform and scientific rationale for MIV-818 | Dr Fredrik Öberg, CSO Medivir |
| 15.30-16.10 | Current status of the development of MIV-818 | Dr Karin Tunblad, MIV-818 project leader |
| 16.10-16.30 | Summing up | Dr Uli Hacksell, CEO Medivir |
| 16.30-17.30 | Mingel |
Warm welcome!
For further information, please contact:
Uli Hacksell, CEO, Medivir AB, phone: +46 (0)8 5468 3100.
About MIV-818
MIV-818 is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug to benefit patients with HCC and other forms of liver cancer. A phase I study is ongoing in liver cancer patients.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
Tags: